CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: (1) PROPOSED GRANT OF OPTIONS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP; (2) NOTICE OF EXTRAORDINARY GENERAL MEETING; AND (3) CLOSURE OF REGISTER OF MEMBERS FOR THE EXTRAORDINARY GENERAL MEETING
CSTONE PHARMA-B: BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING
CSTONE PHARMA-B: GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 460,000 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 3,732,500 SHARES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 501,000 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 3,272,500 SHARES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
CSTONE PHARMA-B: (1) PROPOSED RE-GRANTS OF SHARE OPTIONS TO EXISTING GRANTEES UNDER THE POST-IPO ESOP; (2) PROPOSED GRANT OF SHARE OPTIONS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP; (3) PROPOSED AMENDMENTS TO THE POST-IPO ESOP; (4)
CSTONE PHARMA-B: PLACING OF NEW SHARES UNDER GENERAL MANDATE
CSTONE PHARMA-B: (I) PROPOSED CANCELLATION AND RE-GRANTS OF OPTIONS TO EXISTING GRANTEES UNDER THE POST-IPO ESOP; AND (II) PROPOSED AMENDMENTS TO THE SHARE INCENTIVE SCHEMES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: GRANT OF OPTIONS PURSUANT TO THE POST-IPO ESOP
CSTONE PHARMA-B: GRANT OF OPTIONS PURSUANT TO THE POST-IPO ESOP
CSTONE PHARMA-B: GRANT OF OPTIONS PURSUANT TO THE POST-IPO ESOP
CSTONE PHARMA-B: EXCHANGE NOTICE - RESUMPTION OF TRADING
CSTONE PHARMA-B: SUSPENSION OF TRADING IN SHARES
No Data